Asset overview
Program snapshot
Target: Unknown
Cell type: NK_CELL
Indications: Unresectable Melanoma, Metastatic Cutaneous Melanoma, Metastatic Uveal Melanoma
Sponsor: Beijing Biotech
Institution: Beijing Biotech
Car Nk
EB-DTKN-401 allogeneic dual-target CSPG4/GD2 CAR-NK cells
EB-DTKN-401 allogeneic dual-target CSPG4/GD2 CAR-NK cells is flagged as a low confidence because it has an active early-phase oncology cell-therapy trial at Beijing Biotech, with a unlinked patent signal linked through public patent-search heuristics. Manual review is still required.
Clinical evidence
Trial footprint
Phase: Phase1
Status: Recruiting
Trial count: 1
Active trials: 0
First posted: June 4, 2026
Last updated: June 4, 2026
Signal summary
IP and BD posture
IP signal: Unlinked
BD label: Low Confidence
Confidence: Low
Manual review required: Yes
Scores
Deterministic scoring
Clinical translation3
IP linkage0
Licensing clarity2
Strategic interest3
Source
Public trial record
Review the underlying ClinicalTrials.gov record and treat Treelip output as a prioritization layer, not a final diligence conclusion.
NCT IDs: NCT07627698